Collaboration Molecule definition

Collaboration Molecule means each of the [***] Molecule and the MGNX Option Molecule.
Sample 1Sample 2Sample 3
Collaboration Molecule means (a) MDV3100, (b) any Other Patented Molecule or (c) any metabolite, salt, hydrate, solvate, isomers, enantiomers, free acid form, free base form, crystalline form, pro-drug (including ester pro-drugs) form, racemate or optically active form of any compound described in clause (a) or (b).
Sample 1Sample 2
Collaboration Molecule means any therapeutic agent that (a) (i) binds to and modulates the activity of a Cardiomyopathy Target or (ii) expresses, in whole or in part, a Cardiomyopathy Target ((i) or (ii), “directed against” a Cardiomyopathy Target) and (b) (i) is Covered by a Fulcrum Patent Right that claims or discloses a method of using such therapeutic agent, (ii) with respect to which MyoKardia or any of its Affiliates or Licensees has initiated Lead Optimization within [**] after the Final Data Package Delivery Date or (iii) MyoKardia or any of its Affiliates or Licensees has in-licensed or acquired within [**] after the Final Data Package Delivery Date, (whether or not, in the case of clause (ii) or this clause (iii), Covered by a Fulcrum Patent Right); provided that [**] (collectively, the “Exceptions”) will not be deemed a Collaboration Molecule.
Sample 1

Examples of Collaboration Molecule in a sentence

  • For the avoidance of doubt and without limitation, both Parties shall have the right to propose to the JDC any studies of the MDV3100 Product not then part of a Joint Development Plan, or the expansion of development of the MDV3100 Product to include any new indication(s) within the Field, or the development of any Collaboration Molecule other than MDV3100.

  • After exercise of the License Option for a Pharmacological Profile, JBI shall be free to publish any academic, scientific, medical or other publication or presentation containing Confidential Information or containing or referring to or otherwise relating to a Collaboration Molecule, Lead [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED.

  • For clarity, JBI shall not have a license from Scholar Rock to Commercialize any Collaboration Molecule, Lead Molecule or Licensed Product unless and until JBI has exercised its License Option in accordance with Section 2.2 for Collaboration Molecules with such Pharmacological Profile.

  • Other representatives of each Party involved with the Collaboration Molecule, Lead Molecule or Licensed Product may attend meetings as non-voting participants, subject to the confidentiality provisions set forth in ARTICLE 10.

  • In particular, studies address the distinct role played by cultural dimensions in different innovation processes, including new product development (Jassawalla & Sashittal, 2002), service innovation (Kenny & Reedy, 2006), administrative innovation (Kenny & Reedy, 2006), and process innovation (Lyons et al., 2007; Kalyar & Rafi, 2013).

  • On a Pharmacological Profile-by-Pharmacological Profile basis, Scholar Rock will notify the Program Committee upon designating that a Collaboration Molecule should be a Lead Molecule for such Pharmacological Profile based upon satisfaction of the Lead Criteria.

  • For the three (3) year period following expiration of the Exclusivity Period, Licensee will have a right of first negotiation (“RFN”) with respect to all molecules (other than Molecules) associated with any pain targets that are identified under the Research Program; provided Licensee may not exercise the RFN unless and until (i) Licensee exercises the Option and makes the Option Exercise Payment and (ii) Licensee had pursued or is pursuing the development of a Collaboration Molecule.

  • The following restrictions shall apply on a Pharmacological Profile-by-Pharmacological Profile basis with respect to any academic, scientific, medical or other publication or presentation or other disclosure by Scholar Rock or JBI that contains or refers to or otherwise relates to any Collaboration Molecule, Lead Molecule or Licensed Product prior to exercise of the License Option for such Pharmacological Profile.

  • ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED Scholar Rock or its Affiliate or sublicensee on all sales of such Licensed Product(s) or products incorporating the same Collaboration Molecule or Lead Molecule as a terminated Licensed Product (collectively “Returned Product”).

  • For purposes of this Supplemental Agreement and the Collaboration Agreement, “Shared Program Activities” shall have the meaning set forth in the Collaboration Agreement, provided that activities with respect to a Collaboration Molecule or Product shall be understood to include activities with respect to a Product that consist of activities directed to the development or commercialization of (i) the CDx for use with the Product or (ii) the Product for use in conjunction with the CDx.


More Definitions of Collaboration Molecule

Collaboration Molecule means any therapeutic agent that is directed against or expresses, in whole or in part, a [**] Target; provided that any therapeutic agent created solely or jointly by Fulcrum, its Affiliates or Third Parties acting on its or their behalf outside the scope of the activities under this Agreement and without the use of any (i) Acceleron Technology, (ii) Confidential Information of Acceleron, (iii) Fulcrum Technology, (iv) Confidential Information of Fulcrum or (v) any other results or data, in the case of (iii), (iv) and (v), generated in the performance of or arising out of the Research Activities, will not be deemed a Collaboration Molecule.
Sample 1
Collaboration Molecule means an agonist of the molecular target known as Stimulator of Interferon Genes (“STING”), which agonist is owned or Controlled by either Party at the Effective Date or by either or both Parties during the Term, [ * ].
Sample 1

Related to Collaboration Molecule

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Licensed Compound means (a) 3,4-Diaminopyridine, the chemical structure of which is set forth on Exhibit B-2; and (b) any derivatives, isomers, metabolites, prodrugs, acid forms, base forms, salt forms, or modified versions of such compound in (a).

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Collaboration has the meaning set forth in Section 2.1.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Research Program has the meaning set forth in Section 2.1.

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Collaborating physician means the physician who,

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Collaborative matter means a dispute, transaction, claim, problem, or issue for resolution, including a dispute, claim, or issue in a proceeding, that is described in a collaborative law participation agreement and arises under the family or domestic relations law of this state, including any of the following:

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Research Program Term has the meaning set forth in Section 2.2.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Compounds means a small molecule HMT inhibitor.

  • Research Plan shall have the meaning set forth in Section 2.1.

  • Development Program means the implementation of the development plan.

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Diagnostic Product means In Vitro Diagnostics, In Vivo Diagnostic Agents and any product used for Diagnosis.

  • Licensed Product means any method, process, composition, product, service, or component part thereof that would, but for the granting of the rights set forth in this Agreement, infringe a Valid Claim contained in the Licensed Patents.

  • Manufacturing Technology means any and all patents, patent applications, Know-How, and all intellectual property rights associated therewith, and including all tangible embodiments thereof, that are necessary or useful for the manufacture of adeno- associated viruses, adeno-associated virus vectors, research or commercial reagents related thereto, Licensed Products, or other products, including manufacturing processes, technical information relating to the methods of manufacture, protocols, standard operating procedures, batch records, assays, formulations, quality control data, specifications, scale up, any and all improvements, modifications, and changes thereto, and any and all activities associated with such manufacture. Any and all chemistry, manufacturing, and controls (CMC), drug master files (DMFs), or similar materials provided to regulatory authorities and the information contained therein are deemed Manufacturing Technology.